NCT07138976

Brief Summary

Endoscopic ultrasound (EUS) and ultrasound (US) are the two primary imaging modalities used to guide pancreatic needle biopsy. This study aimed to compare the diagnostic performance and complications associated with EUS- and US-guided pancreatic biopsies.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,517

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2025

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 17, 2025

Completed
1 day until next milestone

Study Start

First participant enrolled

August 18, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 24, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

August 24, 2025

Status Verified

August 1, 2025

Enrollment Period

5 months

First QC Date

August 17, 2025

Last Update Submit

August 17, 2025

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

  • diagnostic inaccuracy

    1-year

Interventions

sampling tissueOTHER

EUS- and US- guided pancreatic biopsy

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

consecutive patients with focal pancreatic disease underwent procedures for pancreatic tissue acquisition

You may qualify if:

  • Between January 2017 and December 2023, 2663 consecutive patients with focal pancreatic disease underwent 2729 procedures for pancreatic tissue acquisition from focal pancreatic lesions at seven university teaching hospitals in China.

You may not qualify if:

  • Patients were excluded from the study if they had less than 12 months of follow-up, were lost to follow-up, had incomplete follow-up data, or underwent intraoperative biopsy or fluid aspiration.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Tian'an Jiang

Study Record Dates

First Submitted

August 17, 2025

First Posted

August 24, 2025

Study Start

August 18, 2025

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

August 24, 2025

Record last verified: 2025-08